Thematic Tech Transfer (TTT) Program Awarded

− 2 min read

DCVA (Dutch Cardiovascular Alliance), RegMed XB, BioGeneration Ventures (BGV) and its fund FIRST proudly announce that their joint Thematic Tech Transfer (TTT) program has been awarded €10 million in funding by the Netherlands Enterprise Agency (RVO), on behalf of the Ministry of Economic Affairs.

The program aims to accelerate the translation of academic research into innovative companies focused on addressing chronic diseases.

Thanks to this funding, the successful TTT collaboration between DCVA, RegMed XB, and BGV/FIRST will not only be able to continue its impactful work, but also expand its scope, now with the active participation of four leading health foundations: the Dutch Kidney Foundation, Dutch Heart Foundation, Dutch Brain Foundation, and Dutch Diabetes Foundation. This expansion further strengthens the bridge between academic research, entrepreneurship, and societal impact, with the goal of bringing groundbreaking innovations to patients faster.

By combining training, mentoring, and access to funding, the program helps researchers make the leap from lab to market. The focus is on translational innovation: projects that are not only have exceptional science but also have the potential to deliver both clinical and societal impact.

The first TTT program (2020–2024) proved the impact of an integrated approach, supporting researchers nationwide in building business models, securing funding, and launching spin-offs. With 42 voucher projects and 14 start-ups created, 7 of which have already attracted investors, participating companies have raised over €43 million in follow-on investments. The new program builds on this success, accelerating the translation of scientific breakthroughs into solutions for chronic diseases.

With the launch of this new program, partner BioGeneration Ventures (BGV) is establishing FIRST II, a new pre-seed investment fund focused on chronic diseases. Building on the success of the original FIRST fund, which provided early financing to promising life sciences start-ups emerging from Dutch research, FIRST II will continue to bridge the gap between academic innovation and venture investment. Further details about the fund will be announced soon, follow RegMed XB on LinkedIn for udates. 

Continuing the TTT program means that funding in the form of vouchers, will again be available for research projects with valorization potential in the field of chronic diseases.

Would you like to know more about the vouchers? Please contact one of the Impact Officers.